Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Caribou Biosciences, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 126 | 121 | −5 |
| Shares | 45.0M | 43.7M | −1.24M (−2.7%) |
| Value | $238.3M | $185.5M | −$52.8M (−22.2%) |
New holders (19)
Institutions that held Caribou Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Walleye Capital LLC | 494,112 | $2.10M | 0.04% |
| Jane Street Group, LLC | 172,315 | $732.3K | 0.00% |
| Trexquant Investment LP | 88,867 | $377.7K | 0.01% |
| Qube Research & Technologies Ltd | 83,612 | $355.4K | 0.00% |
| HRT Financial LP | 77,467 | $329.0K | 0.00% |
| Prudential Financial Inc | 68,424 | $290.8K | 0.00% |
| Two Sigma Investments, LP | 49,626 | $210.9K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 44,155 | $187.7K | 0.02% |
| ExodusPoint Capital Management, LP | 39,350 | $167.0K | 0.00% |
| Public Employees Retirement System of Ohio | 37,700 | $160.0K | 0.00% |
| Exchange Traded Concepts, LLC | 29,068 | $123.5K | 0.00% |
| Prelude Capital Management, LLC | 23,900 | $101.6K | 0.01% |
| Walleye Trading LLC | 23,204 | $98.6K | 0.01% |
| State Board of Administration of Florida Retirement System | 16,150 | $68.6K | 0.00% |
| Belvedere Trading LLC | 15,099 | $64.2K | 0.02% |
| Ergoteles LLC | 12,500 | $53.1K | 0.00% |
| Centiva Capital, LP | 10,657 | $45.3K | 0.00% |
| Venturi Wealth Management, LLC | 100 | $425 | 0.00% |
| Sofos Investments, Inc. | 4 | $4 | 0.00% |
Sold out (24)
Institutions that held Caribou Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.